research
A KRAS Vaccine Reaches People Before Cancer Does
A first-in-human phase 1 study found durable mutation-targeted immune responses in people at elevated pancreatic-cancer risk.
Summary
A first-in-human phase 1 study found durable mutation-targeted immune responses in people at elevated pancreatic-cancer risk.
Johns Hopkins researchers tested mKRAS-VAX in 20 people who had hereditary risk for pancreatic cancer and an abnormality visible on pancreatic imaging. The peptide vaccine targets six common KRAS mutations found in most pancreatic cancers and many precursor lesions. Investigators reported that it was safe in this small phase 1 group and generated durable immune responses intended to recognize mutation-bearing cells before invasive cancer develops. The study establishes feasibility and immune activity, not cancer prevention; larger and longer trials are needed to determine whether vaccination reduces diagnoses or mortality.
Why it matters
A first-in-human phase 1 study found durable mutation-targeted immune responses in people at elevated pancreatic-cancer risk.
Limits and context
- The study establishes feasibility and immune activity, not cancer prevention; larger and longer trials are needed to determine whether vaccination reduces diagnoses or mortality.
Key claims
A first-in-human phase 1 study found durable mutation-targeted immune responses in people at elevated pancreatic-cancer risk.
Qualification: The study establishes feasibility and immune activity, not cancer prevention; larger and longer trials are needed to determine whether vaccination reduces diagnoses or mortality.
Evidence: source-2026-07-16-006
Sources
- Johns Hopkins Medicine via Newswise: Experimental KRAS vaccineJohns Hopkins Medicine via Newswise · secondary reporting
Corrections
No corrections have been recorded for this story.